Last Updated on December 31, 2023 by The Health Master
USFDA issues Form 483
The U.S. Food and Drug Administration (USFDA) recently completed a pre-market inspection of Gland Pharma’s Pashamylaram facility in Hyderabad. The USFDA also issued Form 483 with two observations.
This article delves into the details of the inspection, the observations made, and Gland Pharma’s response to ensure compliance with quality standards.
Inspection Details and Observations:
The inspection, carried out by the Office of Medical Device and Radiological Health Operations of the USFDA, covered the assessment of Gland Pharma’s adherence to the quality system and current good manufacturing practice regulations for medical devices, as outlined in 21 CFR Part 820.
The inspection took place over a four-day period, from August 23 to August 26.
During the inspection, Gland Pharma’s Pashamylaram facility was evaluated, with a particular focus on its production of generic injectables.
The company had filed an Abbreviated New Drug Application (ANDA) for a specific product intended to be manufactured using a PEN (Pre-filled Syringe) device at the mentioned facility.
The outcome of the inspection resulted in the issuance of Form 483, a document issued by the USFDA to notify a company of any deviations or observations found during inspections. Gland Pharma received two observations on this Form 483.
Importantly, it’s worth noting that there were no observations related to data integrity, indicating that the company’s data management processes were in accordance with regulatory standards.
Gland Pharma’s Response on Form 483:
In response to the observations highlighted in Form 483, Gland Pharma has expressed its full commitment to addressing the identified issues promptly and effectively.
The company recognizes the importance of compliance with regulatory requirements to ensure the safety and efficacy of its medical products.
Gland Pharma has outlined its plan to meticulously address each observation mentioned in Form 483.
The company is dedicated to rectifying any deviations from the established quality standards and implementing the necessary corrective actions.
Furthermore, Gland Pharma has assured its stakeholders that it will submit a comprehensive and timely response to the USFDA, demonstrating its dedication to resolving the observations within the stipulated timeframe.
Conclusion:
The recent pre-market inspection of Gland Pharma’s Pashamylaram facility by the USFDA underscores the significance of maintaining high-quality manufacturing practices in the pharmaceutical industry.
With a commitment to rectify the observations made during the inspection, Gland Pharma aims to uphold its reputation as a reliable provider of medical products and ensure the continued safety and efficacy of its offerings.
Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.
USFDA issued EIR to Torrent Pharma: Gujarat
Procedural lapses flagged at Aurobindo Pharma by USFDA: Telangana
USFDA completes PADE inspection at Marksans with 2 observations
USFDA concludes inspection at Granules Pharma with zero observations
USFDA concludes inspection at Gland Pharma with zero observation
Understanding GMP, cGMP, and WHO-GMP
Quality Assurance in the Pharmaceutical Industry
Duties and responsibilities of QA person in Pharma Industry
Difference: Disintegration and Dissolution test in pharma industry
Understanding DQ, IQ, PQ, and OQ in the Pharma Industry
Regulation of E-Pharmacies: Stakeholder meeting with DCGI
NABL certification for Laboratories: Let’s understand
USFDA approval granted for Generic Pirfenidone Tablets
Huge quantities of drugs seized from Nigerian: UP
NMC Puts New Medical Practitioner Conduct Rules on Hold
Drug alert: 51 out of 1306 samples declared as NSQ in July 2023
Pharmacy Practice Regulations 2015 implemented: Mizoram
Recommendations for expediting TMR for Medical Devices
Key Requirements for RTI Orders: High Court’s Directives
Gujarat FDCA: M-Governance soon for Drug Manufacturers and Medical Stores
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
